Standout Papers

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production 2014 2026 2018 2022 625
  1. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production (2014)
    Aurora Merovci, Carolina Solis‐Herrera et al. Journal of Clinical Investigation
  2. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition (2016)
    Ralph A. DeFronzo, Luke Norton et al. Nature Reviews Nephrology
  3. Insulin: The master regulator of glucose metabolism (2022)
    Luke Norton, Chris E. Shannon et al. Metabolism

Immediate Impact

8 from Science/Nature 64 standout
Sub-graph 1 of 20

Citing Papers

Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
2025 Standout
Human assembloid model of the ascending neural sensory pathway
2025 StandoutNature
2 intermediate papers

Works of Luke Norton being referenced

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
2016 Standout
Chromatin occupancy of transcription factor 7-like 2 (TCF7L2) and its role in hepatic glucose metabolism
2011
and 1 more

Author Peers

Author Last Decade Papers Cites
Luke Norton 1574 2201 1337 54 3.3k
Silvia Frascerra 1242 2203 1371 53 3.8k
Ole Schmitz 1510 2209 1480 55 3.5k
Michael Mark 1213 2103 1195 49 3.0k
Giuseppe Daniele 1049 1608 975 61 2.6k
David Polidori 1285 3128 2001 64 3.9k
Yukiko Onishi 1543 1526 676 75 3.6k
Steven C. Griffen 877 1776 1085 42 2.9k
Linda Morrow 1095 1795 1124 81 3.5k
Roy Eldor 1056 1694 1110 68 2.8k
Nicolas Wiernsperger 1692 1192 740 95 3.7k

All Works

Loading papers...

Rankless by CCL
2026